BioSpace News Archive

Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, informs its shareholders that an Extraordinary General Meeting of the Company will be held on Wednesday February 15, 2023, at 2.00 pm CET at the headquarter of Pixium Vision, 74 rue du faubourg Saint Antoine in Paris.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”) today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 1,940,299 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering.

More than 40 leading ophthalmologists, vision researchers, and public health/policy experts are sharing data and holding discussions on the global burden of diabetes-related eye disease to develop a plan to address this leading cause of blindness at the 2nd Mexico-U.S. Symposium on Vision Health.

Ipsen announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended not to grant marketing authorization for investigational palovarotene as a treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva.

Oxurion NV has entered into an amendment of its mandatory convertible bonds issuance and subscription agreement with the Negma Group on January 25, 2023.

ORION CORPORATION announced Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer.

Sol-Gel Technologies, Ltd. announced today the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from PellePharm, Inc.

SK bioscience shared a development history of the South Korea’s first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in the Kingdom of Saudi Arabia (KSA).

Applied UV, Inc. today announced that it has engaged the services of Herrick, Feinstein LLP to investigate potential illegal short selling of the Company’s stock.

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl ® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia.